Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 37, 2209-2213, July 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benedict, W. F.
Right arrow Articles by Ames, B. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benedict, W. F.
Right arrow Articles by Ames, B. N.

Mutagenicity of Cancer Chemotherapeutic Agents in the Salmonella/Microsome Test

William F. Benedict1, Mary S. Baker, Lynne Haroun, Edmund Choi and Bruce N. Ames2

Division of Hematology-Oncology, Department of Medicine, Childrens Hospital, Los Angeles, California 90027 [W. F. B., M. S. B.], and Department of Biochemistry, University of California, Berkeley, California 94720 [L. H., E. C., B. N. A.]

Seventeen cancer chemotherapeutic agents were tested for their ability to mutate Salmonella typhimurium tester strains in the Salmonella/microsome mutagenicity test. There was a high correlation between the mutagenicity and carcinogenicity of a given agent. Carcinogens positive in the test were Adriamycin, daunomycin, 1-propanol-3,3'-iminodimethanesulfonate, cyclophosphamide, isophosphamide, hycanthone, chlornaphazin, nitrogen mustard, uracil mustard, melphalan, and thio-tepa. Two carcinogens, actinomycin D and bleomycin, were not detected as mutagens. The presumptive noncarcinogen, methotrexate, was negative in the test. Tilorone and 6-mercaptopurine, tentatively classified as noncarcinogens, were mutagenic. The carcinogenicity of cis-dichlorodiammineplatinum(II), which was positive in the test, has not been determined.

1 Recipient of Grant CA-14226 from the National Cancer Institute, NIH, and the Council for Tobacco Research, U.S.A., Inc., and Career Development Award CA-70996 from the National Cancer Institute. To whom requests for reprints should be addressed.

2 Recipient of Energy Research and Development Administration Contract E (04-3)34, PA156.

Received 12/28/76. Accepted 4/15/77.




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Zhu, P. A. Hofmann, and J. K. Buolamwini
Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2921 - H2926.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1977 by the American Association for Cancer Research.